Pritumumab

Day One Receives FDA Rare Pediatric Disease Designation for DAY101 for the Treatment of Pediatric Low-Grade Glioma

Retrieved on: 
Tuesday, July 27, 2021
Health sciences, Health, Life sciences, Biotechnology law, Drug discovery, Pharmaceuticals policy, Orphan drugs, Glioma, Breakthrough therapy, Food and Drug Administration, Zotiraciclib, Pritumumab

In addition to FDA Rare Pediatric Disease Designation, DAY101 has been granted Breakthrough Therapy designation by the FDA for the treatment of patients with pLGG harboring an activating RAF alteration who require systemic therapy and who have either progressed following prior treatment or who have no satisfactory alternative treatment options.

Key Points: 
  • In addition to FDA Rare Pediatric Disease Designation, DAY101 has been granted Breakthrough Therapy designation by the FDA for the treatment of patients with pLGG harboring an activating RAF alteration who require systemic therapy and who have either progressed following prior treatment or who have no satisfactory alternative treatment options.
  • In addition, DAY101 has received Orphan Drug designation from the FDA for the treatment of malignant glioma and orphan designation from the European Commission for the treatment of glioma.
  • The FDA has also granted Rare Pediatric Disease Designation to DAY101 for the treatment of low-grade gliomas harboring an activating RAF alteration that disproportionately affects children.
  • In addition, DAY101 has received Orphan Drug designation from the FDA for the treatment of malignant glioma and orphan designation from the European Commission for the treatment of glioma.

Vir Biotechnology Publishes New Research Characterizing Antibody Response to SARS-CoV-2 in the Journal Cell

Retrieved on: 
Thursday, September 24, 2020
Sarbecovirus, Medicine, Medical specialties, Health, Zoonoses, Medical research, Bat virome, Vaccines, Severe acute respiratory syndrome, Antibody, Pritumumab, Antibody-dependent enhancement

SAN FRANCISCO, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the online publication of new research characterizing differences in antibody responses to SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2).

Key Points: 
  • SAN FRANCISCO, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the online publication of new research characterizing differences in antibody responses to SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2).
  • The results were published "online first in the peer-reviewed journal Cell and will appear in the November 12, 2020, print edition of the journal.
  • This study provides new information about the diverse individual antibody response to SARS-CoV-2 infection.
  • The results establish a blueprint that could help guide future serology studies and inform vaccine and therapeutic design strategies, said Davide Corti, senior vice president of antibody research at Vir and study author.

Nascent Biotech Appoints Chief Medical Consultant in Charge of COVID-19 Research

Retrieved on: 
Wednesday, June 24, 2020
Pritumumab

SAN DIEGO, June 24, 2020 (GLOBE NEWSWIRE) -- Nascent Biotech, Inc. (OTC: NBIO) announced today that it has appointed Dr. Navpaul Singh MD as Chief Medical Consultant in charge of research into Pritumumabs use with viral infections, including COVID-19.

Key Points: 
  • SAN DIEGO, June 24, 2020 (GLOBE NEWSWIRE) -- Nascent Biotech, Inc. (OTC: NBIO) announced today that it has appointed Dr. Navpaul Singh MD as Chief Medical Consultant in charge of research into Pritumumabs use with viral infections, including COVID-19.
  • This opportunity with Nascent Biotechallowsmeto continuemy medical work inviral infections that are with us today andpossiblyin the future.
  • Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers with the approval to begin its open clinical trials.
  • These risks and uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech Inc's ability to raise capital; as well as other risks.

Nascent Biotech to Begin Animal Model Studies for Pritumumab Against Coronaviruses and COVID-19  

Retrieved on: 
Wednesday, June 17, 2020
Medical specialties, Medicine, Pritumumab, Clinical medicine, Biotechnology, Monoclonal antibody

SAN DIEGO, June 17, 2020 (GLOBE NEWSWIRE) -- Nascent Biotech, Inc. (OTCQB: NBIO), today announced after receiving early In-Vitro study results Pritumumab, (PTB), will be advanced to laboratory-based animal studies.

Key Points: 
  • SAN DIEGO, June 17, 2020 (GLOBE NEWSWIRE) -- Nascent Biotech, Inc. (OTCQB: NBIO), today announced after receiving early In-Vitro study results Pritumumab, (PTB), will be advanced to laboratory-based animal studies.
  • Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers.
  • These risks and uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech Inc's ability to raise capital; as well as other risks.
  • Additional information about these and other factors may be described in the Nascent Biotech Inc's Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission.

Nascent Biotech to begin Phase 1 Human Trials for Brain Cancer Drug

Retrieved on: 
Wednesday, May 27, 2020
Medicine, Medical specialties, Clinical medicine, Brain tumor, RTT, Monoclonal antibodies, Immunology, Pritumumab, Glioblastoma

SAN DIEGO, May 27, 2020 (GLOBE NEWSWIRE) -- Nascent Biotech, Inc (OTCQB: NBIO) (the Company or Nascent) is pleased to announce that the Company will soon begin Phase 1 clinical trials for a treatment of Brain Cancer, including, glioblastoma (GBM), the deadliest form of brain cancer.

Key Points: 
  • SAN DIEGO, May 27, 2020 (GLOBE NEWSWIRE) -- Nascent Biotech, Inc (OTCQB: NBIO) (the Company or Nascent) is pleased to announce that the Company will soon begin Phase 1 clinical trials for a treatment of Brain Cancer, including, glioblastoma (GBM), the deadliest form of brain cancer.
  • The PTB antibody is used as a targeted immunotherapy, which unlike chemotherapy, targets only the cancer cells without damaging healthy cells.
  • Our lead candidate, Pritumumab (PTB), is a monoclonal Antibody (Mab) that will be studied in Phase I clinical trials for the treatment of Brain Cancer.
  • These risks and uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech Inc's ability to raise capital; as well as other risks.

Nascent Biotech Provides Shareholder Update on COVID-19 Therapy and Brain Cancer Trials

Retrieved on: 
Wednesday, April 22, 2020
Monoclonal antibodies, Pritumumab

The Companys strategic plans reveal that Nascent is also moving rapidly to human brain cancer trials with its PTB antibody.

Key Points: 
  • The Companys strategic plans reveal that Nascent is also moving rapidly to human brain cancer trials with its PTB antibody.
  • Nascent is currently finalizing the human brain cancer trials timeline, which includes the selection of a Contract Research Organization (CRO) to manage the clinical trials.
  • Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers.
  • These risks and uncertainties include, without limitation, Nascent Biotech Incs ability to target the medical professionals; Nascent Biotech Incs ability to raise capital; as well as other risks.

Nascent Biotech Founder, Dr. Mark Glassy, Will Present at the Clinical Operation in Oncology Trials Meeting, in San Diego in February

Retrieved on: 
Thursday, January 30, 2020
Monoclonal antibodies, Pritumumab

SAN DIEGO, CA , Jan. 30, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE Nascent Biotech, Inc. (OTCQB: NBIO) founder Dr. Mark C. Glassy will be presenting on Navigating the Unique Challenges Presented in Immune Oncology trials in San Diego on February 12th.

Key Points: 
  • SAN DIEGO, CA , Jan. 30, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE Nascent Biotech, Inc. (OTCQB: NBIO) founder Dr. Mark C. Glassy will be presenting on Navigating the Unique Challenges Presented in Immune Oncology trials in San Diego on February 12th.
  • The meeting will be attended by influential leaders in the Pharmaceutical and Investment community.
  • Nascent Biotech, Inc. is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers with an Investigational New Drug (IND) application cleared by the FDA for Phase 1 clinical trials.
  • These risks and uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech Inc's ability to raise capital; as well as other risks.

Nascent Biotech Receives One Million Dollar Commitment From TRITON FUNDS LP

Retrieved on: 
Wednesday, September 11, 2019
Business, Articles, Economy, Pritumumab, Tritón, Entrepreneurship

TRITON FUNDS LP will invest $1 million to support the commencement of Phase I human clinical studies on Nascents primary asset, Pritumumab.

Key Points: 
  • TRITON FUNDS LP will invest $1 million to support the commencement of Phase I human clinical studies on Nascents primary asset, Pritumumab.
  • Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers.
  • TRITON FUNDS creates an ecosystem that assists talented entrepreneurs in successfully growing their ideas and maintaining strong community ethical standards.
  • These risks and uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech Inc's ability to raise capital; as well as other risks.

Nascent Biotech Has Entered into an Agreement to Perform Phase I Clinical Study for Brain Cancer

Retrieved on: 
Monday, August 19, 2019
Pritumumab, Medicine

San Diego, CA, Aug. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (OTCQB: NBIO), today announced they have entered into a contractual agreement in Orange County, CA to conduct Phase I human clinical trials on Nascent antibody, Pritumumab, for the treatment of brain cancer.

Key Points: 
  • San Diego, CA, Aug. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (OTCQB: NBIO), today announced they have entered into a contractual agreement in Orange County, CA to conduct Phase I human clinical trials on Nascent antibody, Pritumumab, for the treatment of brain cancer.
  • "There are significant unmet medical needs in a variety of cancers," said Sean Carrick, CEO of Nascent Biotech.
  • Nascent Biotech, Inc. is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers.
  • These risks and uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech Inc's ability to raise capital; as well as other risks.